A recent study, led by our colleague Dr. Sonya Reid, among over 1,000 women with HR+ HER2- breast cancer found higher proportions of high-risk HR+ HER2- early-stage breast cancer among Black participants. Other findings include:
- Basal-type tumors were more common in Black participants compared with White participants (11% vs. 4.8%)
- Those with basal-type tumors had lower 3-year recurrence-free survival compared to those with Luminal B-type (83.7% vs. 93.7%) and Luminal A-type tumors (83.7% vs. 96.5%)
- Those with high-risk, Luminal B- and Basal-type tumors had significantly worse 3-year outcomes compared to low-risk Luminal A-type tumors
These findings support the prognostic and potentially predictive importance of genomic testing to reduce racial survival disparities among Black women with early-stage breast cancer.
Learn more by reading the article at: https://pubmed.ncbi.nlm.nih.gov/41857012/
Reference: Reid et al. NPJ Breast Cancer. 2026; 12(1):68. PMID: 41857012.
Through ICARE, we aspire to share cancer-related information that may be of interest. If you have questions or clarifications, please direct them to your healthcare provider.
